Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Non Operating Income (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Non Operating Income for 16 consecutive years, with -$12.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 3776.83% year-over-year to -$12.5 million, compared with a TTM value of -$59.7 million through Dec 2025, down 379.3%, and an annual FY2025 reading of -$46.8 million, down 311.36% over the prior year.
  • Non Operating Income was -$12.5 million for Q4 2025 at Arrowhead Pharmaceuticals, up from -$47.4 million in the prior quarter.
  • Across five years, Non Operating Income topped out at $5.6 million in Q2 2021 and bottomed at -$47.4 million in Q3 2025.
  • Average Non Operating Income over 5 years is -$3.3 million, with a median of -$143000.0 recorded in 2021.
  • The sharpest move saw Non Operating Income soared 2657.27% in 2022, then tumbled 3776.83% in 2025.
  • Year by year, Non Operating Income stood at -$707000.0 in 2021, then surged by 148.09% to $340000.0 in 2022, then crashed by 730.59% to -$2.1 million in 2023, then soared by 115.9% to $341000.0 in 2024, then crashed by 3776.83% to -$12.5 million in 2025.
  • Business Quant data shows Non Operating Income for ARWR at -$12.5 million in Q4 2025, -$47.4 million in Q3 2025, and -$176000.0 in Q2 2025.